

Press release  
December 19, 2008  
Gothenburg, Sweden

## New CFO at Vitrolife

Eva Nilsagård has been appointed as the new Head of Vitrolife's Accounting and Finance department and Investor Relations.

Eva is presently Head of Business Support for Region Europe, including Business Control, IT/IS, Quality and Environmental issues at Volvo Penta AB, a supplier of power systems for marine and industrial applications. Previous to that Eva held the position as Group Controller at Astra Tech AB, a med-tech company wholly owned by AstraZeneca.

Eva will start at Vitrolife during the month of March.

December 19, 2008  
Gothenburg, Sweden

Magnus Nilsson  
CEO

### Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.  
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Gothenburg, Sweden, and there are subsidiaries in USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange Stockholm's Nordic Small Cap list.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Securities Exchange and Clearing Operations Act. The information was submitted for publication on December 19, 2008 at 12.00.